HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
HARVARD BIOSCIENCE INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$8.09+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $36.62M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$4.30 (+113.3%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
HARVARD BIOSCIENCE INC saw revenue fall 1.1% to $87.81M over the twelve months to Jun 30, 2026. Free cash flow was -$1.12M, down 123.1% from a year earlier.
Revenue
$87.81M
-1.1% vs. a year earlier
Operating income
-$245.00K
TTM Q2 2026
Free cash flow
-$1.12M
-123.1% vs. a year earlier
EPS, diluted
-$2.35
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $36.62M
- P/E ratio
- –
- Price to sales
- 0.42
- Price to book
- 4.94
- Dividend yield
- –
- Free cash flow yield
- -3.06%
Fundamentals
- Revenue
- $87.81M
- Net income
- -$10.41M
- EPS, diluted
- -$2.35
- Free cash flow
- -$1.12M
- Book value per share
- $1.64
- Diluted shares
- 5M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$87.81M-1.1% YoY
Gross profit
$51.07M+1.1% YoY
Operating income
-$245.00K
Net income
-$10.41M
EPS, diluted
-$2.35
Free cash flow
-$1.12M-123.1% YoY
Reported periodTrailing twelve months